Study paves the way for improving personalized treatment of patients with glioblastoma

2 minutes, 35 seconds Read



A study led by the ITACA Institute of the Universitat Politècnica de València with the participation of the Institut Català d’Oncologia (ICO), the Institut Investigació Germans Trias I Pujol (IGTP) and the Hospital Clínic de Barcelona is a novel approach to improve personalized treatment for glioblastoma patients, which currently exists One of the most aggressive types of cancer. Application of these findings to clinical practice, published in the journal Cancer, has the potential to tailor therapies to the specific characteristics of each brain tumor.

The study focused on evaluating the efficacy of bevacizumab (BVZ) in the treatment of glioblastoma (GBM). This drug is designed to inhibit the formation of new blood vessels in the tumor. However, according to Dr. María del Mar Álvarez-Torres of the Universitat Politínica de Valencia, the efficacy of this treatment has been questioned due to its inability to increase survival in treated patients.

The variability in patient response has raised questions about the generalized utility of this drug in this aggressive form of brain cancer. In this work, we propose using cerebral blood volume (rCBV) as a predictive marker to identify GBM patients who may benefit from this treatment in terms of survival.”

Dr. María del Mar Alvarez-Torres, Università Politínica de Valencia

In their study, the team from UPV, IGTP, ICO and Clinique de Barcelona carried out a retrospective study involving more than 100 patients. Bevacizumab (BVZ) was more beneficial in patients with moderately vascular tumors, with a 10-month longer survival after treatment. This suggests that early tumor vascularity may be an important indicator in predicting who will benefit most from bevacizumab after tumor progression.

“In our study, we discovered that the addition of the rCBV marker allowed us to accurately identify patients with moderately vascularized tumors who would benefit more from bevacizumab treatment. This increase in treatment efficacy not only provides a more targeted approach but also opens the way for patients whose tumors are Exploring more favorable alternatives for those who do not respond positively to medication. This optimized approach helps resource management and contributes to improved clinical outcomes,” explains Maria del Mar Alvarez-Torres.

RCBV UPV (https://www.oncohabitats.upv.es) therefore, it is a non-invasive option with no additional risk to patients. Furthermore, standard diagnostic data avoids additional costs and saves time on other tests.

“Our proposal is an efficient and economically viable option to improve treatment selection. Most importantly, it allows early identification of glioblastoma patients who will benefit most from bevacizumab, facilitating treatment personalization and improving their chances,” said Maria del Mar Alvarez- Torres

The work is now published cancer This is the latest result of the doctoral thesis Maria del Mar at the UPV, specifically the Biomedical Data Science Lab (BDSLab) of the ITACA Institute. He is currently completing his postdoctoral training at Columbia University in New York, one of the world’s leading centers for cancer research.

Source:

Journal Reference:

Del Mar Alvarez-Torres, M., etc. (2023). Unlocking the potential of bevacizumab: rCBVmax as a predictive biomarker for improved survival in glioblastoma IDH-wildtype patients. cancer. doi.org/10.3390/cancers16010161.



Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *